Marker Therapeutics Inc (MRKR)

[MDtoB22]

We’re once again at the mercy of the shorts. Over the past year, the three largest price increases have resulted from the EUA mix-up, Orphan Drug Designation, and most recently an article off Seeking Alpha. Management has remained silent and Peter Hoang has bunkered like his life depends on it. A data update could go a long way, but who knows what, if anything, is in store for shareholders. Hopefully Hoang follows a similar path as SRNE, where they announced turning down buyout offers that were multiples higher than the current stock price. Agopyan is yet to demonstrate her value to the company but that notion is subject to change overnight.